Orbsen Therapeutics to take part in €6m liver disease clinical trial

Apr 01 2014 Posted: 16:14 IST

Orbsen Therapeutics, a spin-out from NUI Galway’s Regenerative Medicine Institute (REMEDI) has announced plans to partner with the University of Birmingham in a €6 million project to fight liver disease.

The stem cell research company, which was founded by Prof Frank Barry and Prof Tom O’Brien in 2006, will collaborate with the university on an EU FP7-funded project known by as Merlin (MEsynchymal stem cells to Reduce Liver INflammation). The project, which is led by Prof Phil Newsome, will advance Orbsen’s proprietary cell therapy to a Phase 2a clinical trial.